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ARTICLE
The Alexander Disease–Causing Glial Fibrillary Acidic Protein
Mutant, R416W, Accumulates into Rosenthal Fibers by a Pathway
That Involves Filament Aggregation and the Association
of aB-Crystallin and HSP27
Ming Der Perng,* Mu Su,* Shu Fang Wen, Rong Li, Terry Gibbon, Alan R. Prescott,
Michael Brenner, and Roy A. Quinlan
Here, we describe the early events in the disease pathogenesis of Alexander disease. This is a rare and usually fatal
neurodegenerative disorder whose pathological hallmark is the abundance of protein aggregates in astrocytes. These
aggregates, termed “Rosenthal fibers,” contain the protein chaperones aB-crystallin and HSP27 as well as glial fibrillary
acidic protein (GFAP), an intermediate filament (IF) protein found almost exclusively in astrocytes. Heterozygous,missense
GFAP mutations that usually arise spontaneously during spermatogenesis have recently been found in the majority of
patients with Alexander disease. In this study, we show that one of the more frequently observed mutations, R416W,
significantly perturbs in vitro filament assembly. The filamentous structures formed resemble assembly intermediates but
aggregate more strongly. Consistent with the heterozygosity of the mutation, this effect is dominant over wild-type GFAP
in coassembly experiments. Transient transfection studies demonstrate that R416W GFAP induces the formation of GFAP-
containing cytoplasmic aggregates in a wide range of different cell types, including astrocytes. The aggregates have several
important features in common with Rosenthal fibers, including the association of aB-crystallin and HSP27. This asso-
ciation occurs simultaneously with the formation of protein aggregates containing R416W GFAP and is also specific,
since HSP70 does not partition with them. Monoclonal antibodies specific for R416W GFAP reveal, for the first time for
any IF-based disease, the presence of the mutant protein in the characteristic histopathological feature of the disease,
namely Rosenthal fibers. Collectively, these data confirm that the effects of the R416W GFAP are dominant, changing
the assembly process in a way that encourages aberrant filament-filament interactions that then lead to protein aggre-
gation and chaperone sequestration as early events in Alexander disease.
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Alexander disease (MIM 203450) is a rare and often fatal
neurological disorder, first described by W. S. Alexander.1
On the basis of age at onset, the disorder has been divided
into three subtypes: infantile, juvenile, and adult.2 The in-
fantile form, with onset between birth and age ∼2 years,
is the most common type and is characterized by extensive
loss of white matter.3–5 A striking neuropathological fea-
ture of all forms of Alexander disease is the presence of
Rosenthal fibers, unique cytoplasmic inclusions within as-
trocytes that contain the major astrocytic intermediate
filament (IF) protein glial fibrillary acidic protein (GFAP)
and the chaperones aB-crystallin and HSP27.6–8 Although
the GFAP within Rosenthal fibers appears disorganized, as-
trocytes in Alexander disease also possess GFAP filaments
with conventional 10-nm morphology.
Recently, missense point mutations in GFAP have been
identified as a genetic basis for Alexander disease.9 To date,
all known mutations have been heterozygous, indicating
that the mutant form of the protein is dominant over the
wild type. This is consistent with the finding of autosomal
dominant mutations in 26 other IF genes that are linked
to human disease,10,11 summarized in the online Inter-
mediate Filament Disease Mutation Database. The list of
known mutations in GFAP now includes 32 nucleotide
changes that affect 24 aa spread throughout the entire
sequence12 (see also the Alexander Disease Web site). The
mutations usually arise spontaneously during spermato-
genesis,13 with familial cases being quite rare because of
the high morbidity associated with the disease. The mu-
tation studied in this report, R416W, is one of the four
mutations reported in familial cases and is also found in
sporadic cases.12
Like other IF family members, GFAP has a characteristic
domain structure comprising a central a-helical rod do-
main flanked by non–a-helical N-terminal “head” and C-
terminal “tail” domains.14 The rod domain contains char-
acteristic heptad repeats of hydrophobic residues, which
are the underlying basis for the coiled-coil dimer in the
filament, and the highly conserved LNDR and TYRK-
LEGGE motifs that are present at the start and the end of
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this central rod domain.10 Both of these motifs are highly
conserved throughout the whole IF family,15 and those
mutations in Alexander disease and other genetic IF pro-
tein disorders found within them usually correlate with
the severest forms of the diseases.10,11 The crystallization
of regions containing these two motifs from vimentin, a
closely related type III IF protein16,17 that coassembles with
GFAP, has provided the atomic structure of these particular
highly conserved motifs. Our knowledge of the important
higher order interactions within the filament, however, is
still limited to low-resolution studies18–20; therefore, the
full structural impact of most of these rod mutations has
not yet been detailed.
One of the other common mutations outside the cen-
tral rod domain of GFAP that causes Alexander disease is
R416W. This mutation occurs in the tail domain within
the RDG motif, which is conserved among all GFAP pro-
teins from multiple species, as well as the related type III
IF proteins vimentin and desmin. Here, we describe the
effects of this mutation on GFAP assembly and use this
R416W GFAP mutant to identify the early events in the
development of Alexander disease.
Material and Methods
Plasmid Construction and Site-Directed Mutagenesis
Total RNA was extracted from human astrocytoma U373MG cells
with the RNeasy kit (Qiagen). The complete human GFAP cDNA
was amplified by RT-PCR, with the SuperScript RT-PCR system
(Invitrogen), with use of oligonucleotides 5′-CATATGGAGAGGA-
GACGCAT-3′ and 5′-TCACATCACATCCTTGTGCT-3′ as forward
and reverse primers, respectively. The amplified PCR product
was cloned into the pGEM-T Easy vector (Promega), to generate
pGEM-T Easy-WTGFAP, and the entire sequence was confirmed
against the GenBank database entry for GFAP (accession number
J04569). The R416W mutation was introduced by QuickChange
site-directed mutagenesis (Stratagene) with use of the pGEM-T
Easy-WTGFAP vector as a template. The following mutagenic ol-
igonucleotides that contained the desired CrT mutation at np
1246 were synthesized: 5′-GAAGACCGTGGAGATGTGGGATGG-
AGAGGTCAT-3′ and 5′-ATGACCTCTCCATCCCACATCTCCACG-
GTCTTC-3′. The amplified PCR product containing the R416W
mutation was cloned into the pGEM-T Easy vector, and the mu-
tation sequence was confirmed by DNA sequencing. For expres-
sion in cultured mammalian cells, both the wild-type and R416W
GFAP cDNA in the pGEM-T Easy vector were subcloned into the
pcDNA3.1() vector (Invitrogen) with use of the XbaI and EcoRI
restriction sites. The GFAP mutant R239C was also subcloned into
pCDNA3.1 from the pRSVi vector21 with use of the restriction
enzyme HindIII. For expression in bacteria, wild-type and R416W
GFAP cDNA samples were subcloned into the pET23b vector (No-
vagen) with use of the NdeI and EcoRI restriction sites.
Expression and Purification of Recombinant GFAPs
For bacterial expression of proteins, pET 23b vector containing
either wild-type or mutant GFAP cDNA samples were transformed
into Escherichia coli strain BL21(DE3) pLysS (Novagen). After trans-
formation, cultures were grown in Luria Bertani medium supple-
mented with appropriate antibiotics to OD600 of 0.5–0.6, and pro-
tein expression was induced by the addition of 0.5 mM isopropyl-
1-thio-b-D-galactopyranoside for 3 h. Overexpressed GFAP formed
inclusion bodies, which were prepared as described elsewhere.22
The final pellets, consisting predominantly of GFAP, were solu-
bilized in extraction buffer (8 M urea, 20 mM Tris-HCl [pH 7.4],
5 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol [DTT], and 1 mM
phenylmethylsulfonyl fluoride [PMSF]) at room temperature for
3 h, and any insoluble material was removed by centrifugation,
at , in a benchtop Optima MAX Ultracentrifuge with100,000 g
use of an MLA-80 rotor (Beckman Coulter). GFAP was further
purified by ion-exchange chromatography with use of a Merck-
Hitachi Biochromatography system equipped with a Fractogel-
EMD TMAE 650S column (Merck) pre-equilibrated in the column
buffer (6 M urea, 10 mM Tris-HCl [pH 8.0], 5 mM EDTA, 1 mM
EGTA, 1 mM DTT, and 1 mM PMSF). GFAP was eluted from the
column with a linear gradient of 0–0.5 M NaCl in the same buffer
over 1 h at a flow rate of 1 ml/min. The GFAP-enriched fractions
were pooled, concentrated, and applied to a Fractogel EMD COO-
650S column (Merck) and were pre-equilibrated with column
buffer (6 M urea, 20 mM sodium formate [pH 4.0], 5 mM EDTA,
1 mM EGTA, 1 mM DTT, and 1 mM PMSF). After washing with
buffer B, GFAP was eluted with a linear gradient of 0–0.5 M NaCl
in the same buffer. Column fractions were analyzed by SDS-PAGE,
and those containing purified GFAP were collected and stored at
80C. Protein concentrations were determined by bicinchonic
acid assay (BCA reagent [Perbio Science]) with use of BSA as
standard.
In Vitro Assembly and Sedimentation Assay
Purified GFAP was diluted to 0.3 mg/ml in 6 M urea in a buffer
of 10 mM Tris-HCl (pH 8.0), 5 mM EDTA, 1 mM EGTA, and 1
mM DTT and was dialyzed stepwise against 3 M urea in the same
buffer for 4–6 h at room temperature and then against the same
buffer without urea overnight at 4C. Filament assembly was com-
pleted by dialyzing against assembly buffer (20 mM imidazole-
HCl [pH 6.8], 100 mM NaCl, and 1 mM DTT) for 12–16 h at room
temperature. The efficiency of in vitro assembly was assessed by
sedimentation assay as described elsewhere.23 In brief, the assem-
bly mixture was layered onto a 0.85-M sucrose cushion in assem-
bly buffer and was centrifuged at for 30 min. To inves-80,000 g
tigate the effect of mutations on filament-filament interactions,
assembled filaments were subjected to low-speed centrifugation
at for 10 min in a bench-top centrifuge (Eppendorf). The3,000 g
supernatant and pellet fractions were analyzed by SDS-PAGE24 and
were visualized by Coomassie blue staining. In some instances,
the proportion of GFAP distributed between pellet and super-
natant fractions was measured using an image analyzer (LAS-
1000plus [FujiFilm]). Coomassie blue signals for individual bands
were quantified using the Image Gauge software (v. 4.0) (FujiFilm).
Electron Microscopy
GFAP was diluted in assembly buffer to 100 mg/ml and was neg-
atively stained with 1% (w/v) uranyl acetate (Agar Scientific).
Samples on carbon-coated copper grids were examined with a
Phillips 400T transmission electron microscope, with use of an
accelerating voltage of 80 kV. Images were acquired at a magni-
fication of on Kodak 4489 film and then were digitized17,000#
at –pixel resolution before being processed further1,200# 1,200
in Adobe Photoshop 7 (Adobe Systems).
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Cell Cultures and Transient Transfection
Human breast cancer epithelial MCF7 cells were obtained from
the European Collection of Cell Cultures (Sigma). Human adrenal
cortex carcinoma SW/cl.1 and SW13/cl.2 cells were kindly pro-
vided by Dr. Robert Evans (University of Colorado Health Sciences
Center, Denver). The human astrocytoma cell line U343MG was
a gift from Dr. Rutka (Toronto), and the cells were grown inaMEM
(Invitrogen). These cells express vimentin and GFAP as well as
HSP27 and aB-crystallin. Primary mouse astrocytes from wild-
type and vimentin/GFAP double-knock littermates were a gen-
erous gift of Dr. Milos Pekny (Go¨teborg, Sweden). They were pre-
pared and grown as described elsewhere.25 Unless otherwise
stated, cells were grown in Dulbecco’s modified Eagle medium
supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine,
100 U/ml penicillin, and 0.1 mg/ml streptomycin (Sigma) and
were maintained at 37C in a humidified incubator of 95% (v/v)
air and 5% (v/v) CO2.
For transient transfection studies, cells grown on 13-mm cov-
erslips at a density of 40%–50% confluency were transfected with
pcDNA3.1() expressing either wild-type or R416W GFAP, with
use of GeneJuice transfection reagent (Novagen) according to the
manufacturer’s protocol. In some experiments, the R239C GFAP21
and myc-tagged ubiquitin (His6-myc-Ubiquitin)
26 were used. Cells
were analyzed by double-label immunofluorescence microscopy
48 h after transfection.
Antibody Production
Mouse monoclonal antibodies were made that specifically rec-
ognized human but not wild-type R416W GFAP. The immuno-
gen was a peptide dodecamer centered on the mutation site,
KTVEMWDGEVIK (Genemed Synthesis), which was linked to
keyhole limpet hemocyanin. Monoclonal antibodies were pro-
duced by the UAB Epitope Recognition Core, which also per-
formed an initial ELISA screen against purified recombinant wild-
type and R416W mutant GFAP. The corresponding wild-type
peptide, KTVEMRDGEVIK, failed to produce monoclonal anti-
bodies specific to the wild-type sequence.
Immunostaining of Cells and Tissues
and Immmunofluoresence Microscopy
Immunocytochemistry of cultured cells was performed on cov-
erslips washed twice with PBS, and the cells were fixed in either
ice-cold methanol/acetone (1:1 [v/v]) for 20 min or in 4% (w/v)
paraformaldehyde/PBS for 10 min. In the case of paraformalde-
hyde fixation, cells were subsequently permeabilized with 0.5%
NP-40 in PBS for 10 min. After being washed twice with PBS
containing 0.02% (w/v) sodium azide and 0.02% (w/v) BSA (PBS/
BSA/azide), cells were blocked with 10% (v/v) goat serum in PBS/
BSA/azide for 20 min and then were incubated with primary an-
tibodies at room temperature for 1 h. The primary antibodies used
in this study were mouse monoclonal anti-GFAP (G-A-5, 1:500
[Sigma]), rabbit polyclonal GFAP antibodies (Z0334, 1:500 [Da-
ko]), monoclonal anti-human GFAP (SMI-21, 1:500 [Sternberger
Monoclonals]), monoclonal anti-keratin 18 (LE41 [kindly pro-
vided by Prof. Birgit Lane, University of Dundee, Dundee, United
Kingdom), monoclonal anti-R416W GFAP (19.2 and 1A3, de-
scribed below, 1:500), rabbit polyclonal anti-GFAP (clone 3270,
1:200),27 polyclonal anti-vimentin (clone 3052, 1:200),28 and the
myc-epitope monoclonal antibody (Clone 9E11, 1:10).29 After
cells were washed with PBS/BSA/azide, the primary antibodies
were detected using Alexa 488 (1:400 [Molecular Probes]) or Alexa
594 (1:600 [Molecular Probes]) conjugated secondary antibodies.
All antibodies were diluted in PBS/BSA/azide buffer. The glass
coverslips were mounted on slides with the fluorescent protecting
agent Citifluor (Citifluor Labs) and were observed with a Zeiss
LSM 510 confocal laser scanning microscope (Carl Zeiss). Optical
sections were set to ∼1.0 mm. Images were processed and prepared
for figures with Adobe Photoshop 7 (Adobe Systems). Quantita-
tion of the GFAP filament phenotypes was by visual assessment
of the cells and by scoring cells for the presence or absence of
GFAP-containing aggregates. Approximately 100–150 transfected
cells were assessed, and each experiment was repeated at least
three times.
Immunohistochemistry from normal human and Alexander
disease brain sections was performed on 6 mm–thick paraffin sec-
tions kindly provided by Drs. Jim Goldman and Goumei Tang
(Columbia Medical School, New York). Internal review board ap-
proval was obtained from Columbia Medical School for these
studies. Archival material for the infantile R416W Alexander dis-
ease case used in this study was described elsewhere.30 Primary
antibodies were rabbit anti-cow GFAP (Z0334, 1:5,000 [Dako]),
and mouse anti-R416W GFAP (19.2, described below, 1:2,000).
Secondary antibody for the peroxidase method was peroxidase-
conjugated donkey anti-mouse IgG (Jackson ImmunoResearch)
(1:2,000), with staining visualized using 3,3′-diaminobenzidine
tetrachloride (DAB, metal-enhanced Substrate Kit [Pierce]). Sec-
ondary fluorescent antibodies are described above. Some sections
were counterstained with Hoechst 33258 (Sigma) to reveal nuclei.
Ultrastructural Analysis by Immunoelectron Microscopy
MCF7 cells grown on 10-cm2 petri dishes (Greiner Bio-One) were
transfected with either wild-type or R416W GFAP for 48 h. Cells
were then fixed directly in 80 mM cacodylate buffer (pH 7.2)
containing 1.25% (v/v) glutaraldehyde and 1% (w/v) paraformal-
dehyde for 30 min at room temperature. Cells were scraped off
the dish by a rubber policeman, were pelleted by low-speed cen-
trifugation, and were washed three times with cacodylate buffer.
The cells were then postfixed with 1% (w/v) osmium tetroxide
in cacodylate buffer. After several washes with distilled water, cells
were subjected to a series of graded ethanol dehydration, followed
by overnight incubation in 1:1 propylene oxide:epoxy resin
(Durcupan [Sigma]). After two changes of 100% fresh resin, cell
pellets were transferred to BEEM capsules (Agar Scientific) and
were polymerized in fresh resin overnight at 60C. Ultrathin sec-
tions were generated using a Leica Ultracut ultramicrotome and
were collected on pioloform and carbon-coated nickel grids (Agar
Scientific). The grid specimens were then etched with 1% periodic
acid, and osmium was removed by 2% (w/v) sodium periodate
before incubation with blocking solution consisting of 0.5% (w/
v) fish skin gelatin (Sigma) in PBS. Subsequently, sections were
incubated with polyclonal anti-GFAP antibodies (clone 3270) di-
luted 1:20 in blocking solution for 90 min, were washed three
times in PBS, and then were incubated with protein A conjugated
with 5-nm gold particles (British BioCell International) for 2 h.
After several washes in distilled water, specimens were stained
with saturated aqueous uranyl acetate (3% [w/v]) for 30 min,
followed by staining with lead citrate for 30 min.31 Stained sam-
ples were subsequently examined on an FEI Tecnai 12 transmis-
sion electron microscope (FEI).
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Figure 1. The dominant effect of R416W GFAP, revealed by in vitro assembly studies. Purified GFAP at a concentration of 0.3 mg/ml
was assembled in vitro by stepwise dialysis into assembly buffer, as described in the “Material and Methods” section. Assembled filaments
were negatively stained and were visualized by transmission electron microscopy. Under these assembly conditions, wild-type GFAP
assembled into typical 10-nm filaments with length of several microns (A), whereas R416W GFAP alone and in different proportions
with wild-type protein formed short filamentous intermediates that had a strong tendency to aggregate (B–E). It is difficult to see the
structural detail of the aggregates formed by R416W GFAP (D) and mixtures thereof (B and C) when negatively stained with uranyl
acetate. Sometimes, less aggregated material can be found, and then, at higher magnification (E), the filamentous structures that
comprise the aggregates are clearly seen. Mixing wild-type GFAP in either 75:25 (B) or 50:50 (C) proportions with R416W GFAP failed
to rescue intermediate filament formation, and similar aggregates were formed (B and C). A low-speed sedimentation assay was used
to assess the extent of this aggregation. F, Wild-type (WT) (lanes 1 and 2) and R416W GFAP (lanes 7 and 8) were assembled, either
individually or in mixtures of 75:25 (lanes 3 and 4) or 50:50 (lanes 5 and 6) WT:R416W GFAP. After assembly, the samples were subjected
to low-speed centrifugation, and the resulting supernatant (S) and pellet (P) fractions were analyzed by SDS-PAGE and were visualized
by Coomassie blue staining. Whereas only one-third of assembled wild-type GFAP was sedimented (lane 1), almost all the R416W mutant
was found in the pellet fraction (lane 8). Mixing wild-type GFAP with the R416W mutant in different proportions did not dramatically
increase the GFAP signal in either the supernatant fraction of the 50:50 mixture (lane 5) or the 75:25 mixture (lane 3). These data
show that the effects of R416W GFAP on in vitro filament assembly is dominant over the wild-type protein. Bars p 1 mm, except in
panel E, where it is 0.1mm.
Preparation of Cytoskeletal Fractions and Immunoblotting
Analysis
Cells grown on 10-cm2 petri dishes were transfected with control
vector (pcDNA3.1) or vectors containing either wild-type or
R416W GFAP cDNA. At 48 h after transfection, cells were lysed
using two different extraction buffers, designed to test the resis-
tance of GFAP filaments and aggregates to extraction. In the mild
extraction protocol, cells were lysed on ice for 15 min in 1 ml
mild extraction buffer (MEB; 20 mM Tris-HCl [pH 7.6], 140 mM
NaCl, 5 mM EDTA, 1 mM EGTA, 0.5% [v/v] NP-40 supplemented
with Complete protease inhibitor cocktail [Roche Diagnostics],
and 1 mM PMSF). In the more severe extraction protocol, cells
were lysed in 1 ml of a harsher extraction buffer (HEB) containing
deoxycholate (20 mM Tris-HCl [pH 7.6], 140 mM NaCl, 5 mM
EDTA, 1 mM EGTA, 1% [v/v] NP-40, 0.5% [w/v] sodium deoxy-
cholate supplemented with Complete protease inhibitor cocktail
[Roche Diagnostics], and 1 mM PMSF). Cell lysates were collected,
were homogenized in a Dounce homogenizer (Wheaton), and
were centrifuged at for 15 min at 4C. The pellet was16,000 g
resuspended in pelleting buffer (20 mM Tris-HCl [pH 8.0], 10 mM
MgCl2, and 1 mM PMSF) containing 250 U/ml benzonase nucle-
ase (Novagen) and was incubated for 30 min at room temperature.
After repelleting, the final pellets were washed in PBS containing
1 mM PMSF and then were resuspended in Laemmli’s sample
buffer,24 in a volume that was equivalent to the supernatant. Su-
pernatant and pellet fractions were then boiled for 5 min in
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Figure 2. Effect of R416W and R239C mutations on the de novo GFAP IF network formation in IF-free cells. SW13/cl.2 (A–C) and
primary astrocytes derived from GFAP/vimentin-null mice (D-F) were transiently transfected with either wild-type (A and D), R416W (B
and E), or R239C (C and F) GFAP. At 48 h after transfection, the distribution of GFAP was assessed by confocal immunofluorescence
microscopy with use of the rabbit polyclonal anti-GFAP antibody. When expressed in SW13/cl.2 cells, wild-type GFAP assembled into
bundled filaments that extended throughout the cytoplasm (A). In contrast, cells transfected with either R416W (B) or R239C (C) GFAP-
expression plasmids exhibited only GFAP-positive aggregates. In the IF-free mouse astrocytes, wild-type GFAP assembled into extended
filaments at the cell periphery with some perinuclear accumulations (D), whereas R416W mutant GFAP formed punctuate aggregates
scattered throughout the cytoplasm without any detectable filaments (E). Expression of R239C GFAP also induced numerous GFAP
aggregates in the cytoplasm (F). For both R416W and R239C GFAP, all the transfected cells had aggregates. Bars p 10 mm.
Laemmli’s sample buffer, and equal volumes were analyzed by
SDS-PAGE and immunoblotting. Actin was used as a loading con-
trol for these samples.
Immunoblotting was performed using the semidry blotting
method, according to the manufacturer’s specifications (Bio-Rad
Laboratories). After the blotting, protein-transfer efficiency was
assessed by Ponceau S (Sigma) staining of the nitrocellulose mem-
brane, followed by destaining in Tris-buffered saline (TBS; 20 mM
Tris-HCl [pH 7.4], and 150 mM NaCl). Membranes were blocked
for 2 h in blocking buffer containing 5% (w/v) BSA in either TTBS
(TBS containing 0.2% [v/v] Tween 20) or PBST (5% [w/v] nonfat
milk and 0.1% [v/v] Tween-20 in PBS) and were incubated for 2
h with mouse monoclonal anti-GFAP (GA-5), monoclonal anti-
human GFAP (SMI-21), monoclonal anti-actin (AC-40 [Sigma]),
or rabbit polyclonal anti-GFAP antibodies (3270) diluted by 1:
5,000 in blocking buffer. In some experiments, the mouse mono-
clonal antibodies to the c-myc epitope (9E10, diluted by 1:100
in blocking buffer) were used to detect tagged ubiquitin after
transfection. After several washes with TTBS, the membrane was
incubated for 1 h with horseradish peroxidase–conjugated sec-
ondary antibodies (Dako) diluted by 1:2,000 in blocking buffer,
followed by washing with TBS for 30 min. Antibody labeling was
detected by enhanced chemiluminescence (ECL Plus [Amersham
Biosciences]) with use of a luminescent image analyzer (LAS-
1000plus [FujiFilm]). The strength of signal was quantified using
the Image Gauge software (v. 4.0) (FujiFilm).
Immunoblotting of brain samples was performed using anon-
ymous, frozen tissues kindly provided by Drs. Jim Goldman and
Goumei Tang (New York). The tissues were Dounce homogenized
on ice in 10 mM Tris-HCl (pH 7.4), 2 mM b-mercaptoethanol,
0.1 M NaCl, 5 mM EDTA, and 1# protease inhibitor cocktail
(Sigma) at a 10:1 (v/w) buffer:tissue ratio. The homogenate was
centrifuged at for 1 h at 4C, and the pellet was dissolved80,000 g
in ∼15 volumes of the above buffer containing 2% (w/v) SDS.
After determination of protein concentrations with the BCA re-
agent (Pierce), triplicate sets of 500-ng aliquots of each extract
were run on a 10% (w/v) SDS-polyacrylamide gel, with 20-ng
samples of purified recombinant wild-type and R416W GFAP. Af-
ter transfer to Hybond ECL membranes (Amersham Pharmacia
Biotech), the blots were probed with either anti-human GFAP
monoclonal antibody SMI-21 (Sternberger Monoclonal) (1:2,000)
or anti-R416W GFAP monoclonal antibodies 1A3 or 19.2 (1:1,000
dilution). Signals were detected by ECL (Amersham) and were
visualized using a ChemImager 4400 (Alpha Innotech).
Results
Effect of R416W Mutation on In Vitro GFAP Assembly
In vitro assembly studies were performed to determine
how the R416W mutation affects the structural properties
of GFAP filaments. Purified recombinant wild-type and
R416W GFAP, produced in E. coli with a pET-based ex-
pression system, were assembled in vitro by dialysis-based
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Figure 3. The network-forming abilities of the wild-type and R416W GFAP in SW13/cl.1 cells. SW13/cl.1 cells transiently transfected
with either wild-type (A and B) or R416W (C and D) GFAP were fixed at 48 h after transfection and were processed for double-label
confocal immunofluorescence microscopy. GFAP immunofluoresence is shown in panels A and C, whereas the counterstaining for vimentin
is in panels B and D. Notice that wild-type GFAP (A) incorporated into endogenous vimentin (Vim) (B) networks, whereas this is not
the case for R416W GFAP (C). Whereas some transfected cells exhibited one large inclusion with small aggregates at the cell periphery
(arrowheads in C), other transfected cells displayed bundled filaments (arrows in C) that coaligned with the endogenous vimentin (arrows
in D). Bars p 10 mm. (A color version of this figure is available in the online edition of the journal.)
assembly and were visualized by negative staining with
uranyl acetate followed by electron microscopy. Whereas
wild-type GFAP assembled into typical 10-nm filaments
(fig. 1A), R416W GFAP on its own or in combination with
mixtures of wild-type GFAP failed to form extended fila-
ments (fig. 1B–1E). Instead, it formed short rod-like struc-
tures that looked like short filament pieces that had failed
to elongate and compact properly into 10-nm filaments
(fig. 1E). These had a strong tendency to laterally associate
into aggregates (fig. 1D). Because the R416W mutation is
heterozygous in patients with Alexander disease, we also
assessed the assembly behavior of R416W mutant GFAP in
the presence of increasing proportions of wild-type GFAP.
At both 50:50 (fig. 1C) and 75:25 (fig. 1B) proportions of
wild-type:R416W GFAP, normal filament assembly was
disrupted, and aggregates similar to those made by R416W
GFAP alone (fig. 1D) were formed instead. These data in-
dicate that, in vitro, the R416W mutant GFAP acts in a
dominant manner over the wild-type protein. These data
suggested that the assembled R416W GFAP filaments were
prone to aggregation; therefore, we performed a low-speed
centrifugation assay designed to monitor the extent of
filament-filament interactions in the whole filament pop-
ulation.32 With use of this assay, only approximately one-
third of the wild-type GFAP was found in the supernatant
fraction (fig. 1F; e.g., lanes 1 and 2). In contrast, when
assembled on its own, nearly all of the R416W GFAP se-
dimented into the pellet fraction (fig. 1F; e.g., lanes 8 and
7). High-speed centrifugation assay confirmed that the
wild-type GFAP had assembled efficiently, because 190%
of the protein was sedimented under standard centrifu-
gation conditions23,27 (data not shown). Decreasing the
proportion of mutant GFAP in mixtures with wild-type
GFAP (fig. 1F; lanes 3–6) failed to markedly increase the
proportion of soluble material. These data suggest that the
R416W GFAP mutation promotes more interfilament in-
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Figure 4. Expression of R416W mutant in MCF7 cells resulted in the formation of GFAP aggregates. MCF7 cells transfected with either
wild-type (A and B) or R416W GFAP (C and D) were processed at 48 h after transfection for confocal double-label immunofluorescence
microscopy with use of antibodies against GFAP (A and C) and keratin (B and D). When expressed in these cells, wild-type GFAP formed
extended filaments as well as perinuclear filament bundles (A) that partially colocalized with keratin IF networks (arrows in A and B).
In contrast, transfected cells expressing R416W GFAP exhibited large aggregates (C) that also cocollapsed the endogenous keratin IF
networks (arrows in C and D). Bars p 10 mm. (A color version of this figure is available in the online edition of the journal.)
teractions and that this effect is again dominant over the
wild-type protein.
Effect of R416W Mutation on GFAP Network Formation
in Cells Lacking Endogenous GFAP
Transient transfection assays were used to investigate the
effects of the R416W mutation on the formation of GFAP
networks in a range of cell lines that have different IF
compositions. To determine the effect of the R416W mu-
tation on de novo IF network formation, we selected as
the host cells the human adrenocarcinoma-derived SW13/
cl.2 cell line, which does not contain any endogenous
cytoplasmic IFs.33 When expressed in SW13/cl.2 cells,
wild-type GFAP formed filaments (fig. 2A), in agreement
with previous studies.34,35 In contrast, R416W GFAP failed
to assemble into filaments but instead formed clusters of
cytoplasmic aggregates (fig. 2B). Similar results were ob-
served when wild-type (fig. 2D) and R416W plasmids (fig.
2E) were transiently transfected into primary astrocytes
derived from mice lacking GFAP and vimentin.25 For com-
parison, R239C GFAP was also transfected into both these
cell lines (fig. 2C and 2F), and, like R416W GFAP, it also
formed numerous cytoplasmic aggregates when the cyto-
megalovirus promoter was used to drive mutant GFAP ex-
pression. Previous studies have already established that
the R239C mutation in GFAP makes the filaments more
stable and changes the organization of GFAP networks in
transfected cells. Taken together, these data suggest that
the R416W mutation, like the R239C mutation, affects the
ability of GFAP to self-assemble into an extended filament
network in IF-free primary cells and that this deficiency
is independent of the cellular background.
Recent studies have revealed that two or more IF pro-
teins are required for the formation of most normal IF
networks in vivo, including those formed by the type III
IF proteins GFAP, desmin, and vimentin. For instance, des-
min requires paranemin to produce an extended IF net-
work in nonmuscle-derived cell lines.35 Vimentin requires
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Figure 5. Analysis of wild-type and R416W GFAP expression in
transfected MCF7 cells by immunoblotting. MCF7 cells were trans-
fected with either wild-type (lanes 3 and 4) or R416W GFAP (lanes
5 and 6). Untransfected cells were used as a control (lanes 1 and
2). At 48 h after transfection, cells were collected, lysed with MEB,
and centrifuged at for 15 min at 4C. The resulting su-18,000 g
pernatant (S) and pellet (P) fractions were analyzed by SDS-PAGE,
followed by immunoblotting using anti-GFAP (A) and anti-actin
(B) antibodies. The blots were developed by the ECL system. Notice
that, after transfection into MCF7 cells, both wild-type and mutant
GFAP expressed at comparable levels, although proteolyzed GFAP
fragments with slightly higher electrophoretic mobilities were also
detected. Most of the wild-type GFAP was detected in the pellet
fraction (A, lane 4) with a small proportion that remained soluble
(A, lane 3), whereas the R416W GFAP was found exclusively in the
pellet fraction (A, lane 6). Equal loading of each supernatant and
pellet fractions was confirmed by probing with anti-actin antibody
(B).
GFAP to form filaments in astrocytes,36 whereas, in other
cell types, vimentin coassembles with nestin.37 Whereas
GFAP is able to self-assemble into IFs within astrocytes
lacking vimentin, vimentin is required for the correct
spacing of the assembled filaments.36 Therefore, it is im-
portant to assess the assembly behavior of GFAP in cells
containing this key assembly partner.
For these experiments, SW13/cl.1 cells that express vi-
mentin IFs were selected for transient transfection studies.
In this cell line, wild-type GFAP assembled into filamen-
tous networks (fig. 3A) that colocalized with the endog-
enous vimentin IFs (fig. 3B). In contrast, most of the cells
transfected with R416W GFAP contained large aggregates
(fig. 3C; arrows) with small clumps at the cell periphery
(fig. 3C; arrowheads). These aggregates disrupted the en-
dogenous vimentin IF networks, usually causing them to
collapse into a large perinuclear aggregate (Fig. 3D; arrows).
The finding that R416W GFAP caused the collapse of
the endogenous vimentin IF network led us to examine
its effects on keratin networks, IF proteins that do not
coassemble with GFAP. For these experiments, we used
a human breast cancer epithelial MCF7 cell line that ex-
presses only keratin IF proteins (K8, K18, and K19).38
When transfected into this cell line, wild-type GFAP as-
sembled into filaments that tended to bundle in most of
the transfected cells (fig. 4A). The GFAP filament networks
were found to partially coalign with the keratin IF net-
works (fig. 4B; arrows), which is consistent with previous
observations.22,27 In contrast, nearly all MCF cells express-
ing R416W mutant GFAP formed aggregates (fig. 4C; ar-
rows) that often collapsed the endogenous keratin IF
networks (fig. 4D; arrows). These results suggest that the
R416W mutation not only impaired the ability of GFAP
to form normal IF network but also revealed a dominant
effect on endogenous keratin filament networks in the
absence of any obvious coassembly.
The relative expression levels and solubility of the wild-
type and the R416W GFAP were determined by immuno-
blotting of extracts from MCF7 cells prepared using a mild
lysis buffer protocol. Analysis of both supernatant and
pellet fractions revealed no endogenous GFAP expressed
in nontransfected MCF7 cells (fig. 5A; lanes 1 and 2). In
contrast, cells transfected with either wild-type (fig. 5A;
lanes 3 and 4) or R416W (fig. 5A; lanes 5 and 6) GFAP
generated proteins of the expected size at comparable lev-
els, suggesting that aggregate formation is likely due to the
mutation per se rather than elevated expression levels.
Although a small fraction of wild-type GFAP remained in
the supernatant fraction (fig. 5A; lane 3), R416W GFAP
was found exclusively in the pellet fraction (fig. 5A; lane
6), consistent with its sequestration into cytoplasmic ag-
gregates. Equal loading for the various supernatant and
pellet fractions was verified using an anti-actin antibody
(fig. 5B).
Analysis of R416W GFAP Aggregates in MCF7 Cells
by Electron Microscopy
The high transfection efficiency of both wild-type and
R416W GFAP in MCF7 cells allowed us to further analyze
the ultrastructural organization of GFAP by immunoelec-
tron microscopy. MCF7 cells transfected with plasmids ex-
pressing either the wild-type or the R416W GFAP were
processed for immunogold labeling with anti-GFAP anti-
bodies followed by protein A conjugated with 5-nm gold
particles. In cells expressing wild-type GFAP, fibrous re-
gions consisting of 10-nm filaments were observed (fig.
6A and 6B). These filaments were organized into bun-
dles that traversed the cytoplasm (fig. 6A). At a higher
magnification, individual filaments were decorated with
gold particles (fig. 6B; arrows), confirming the presence
of GFAP in these filaments. In contrast, cells expressing
R416W GFAP displayed electron-dense aggregates, distrib-
uted throughout the cytoplasm (fig. 6C; arrows), that were
often accompanied by IFs (fig. 6C; asterisks). At a higher
magnification, these electron-dense aggregates appear as
amorphous membrane-free structures composed of aggre-
gated GFAP, as evidenced by the presence of gold particles
(fig. 6D; arrows).
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Figure 6. Ultrastructural analysis of wild-type and R416W GFAP in MCF7 cells by immunoelectron microscopy. MCF7 cells transfected
with either wild-type (A and B) or R416W (C and D) GFAP were processed at 48 h after transfection for immunogold labeling, as described
in the “Material and Methods” section. Immunogold labeling of ultrathin sections was stained and visualized by a transmission electron
microscope. Wild-type GFAP assembled into filaments that were organized into parallel bundles (A). In contrast, cells expressing the
R416W mutant formed membrane-free irregular-shaped structures composed of electron-dense aggregates at the perinuclear region (C),
often in association with IFs (asterisks [*] in C). Panels B and D are higher magnification views of the boxed areas of panels A and C,
respectively, showing that both the filaments (B) and aggregates (D) were decorated with 5-nm gold particles (arrows in B and D),
confirming the identity of GFAP.
Effects of R416W GFAP on Endogenous GFAP Networks
in Primary Astrocytes
The assembly behavior of R416W GFAP was also examined
in mouse primary astrocytes, to test the effects of endog-
enous wild-type GFAP and vimentin IFs on the aggrega-
tion process. The distribution of transfected GFAP in re-
lation to the endogenous GFAP was visualized by double-
label immunofluorescence microscopy with use of mono-
clonal antibody SMI-21 (fig. 7A and 7C), which specifically
recognizes human GFAP, and polyclonal anti-panGFAP
antibody, which recognizes both the endogenous mouse
GFAP and the transfected human GFAP (fig. 7B and 7D).
Mouse astrocytes transiently transfected with wild-type
GFAP mainly formed filaments (fig. 7A) that colocalized
with the endogenous GFAP network (fig. 7B; arrows). In
contrast, the effects of R416W GFAP expression in astro-
cytes were similar to those observed for the vimentin-con-
taining SW13/cl.1 cells. Most of the transfected cells con-
tained cytoplasmic aggregates with smaller particles at the
cell periphery (fig. 7C), which colocalized with collapsed
endogenous GFAP networks (fig. 7C and 7D; arrows). In
some transfected cells, however, expressed R416W GFAP
was incorporated into the endogenous GFAP networks
without any apparent changes (fig. 7C and 7D; cell on the
right). Careful examination revealed that there were small
aggregates intermingled with the filaments (fig. 7D; ar-
rowheads), which were immunopositive for the human
R416W GFAP, indicative of perhaps an early change in the
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Figure 7. Transient expression of wild-type or R416W GFAP in primary mouse astrocytes. Primary mouse astrocytes were transfected
with either human wild-type (A and B) or R416W (C and D) GFAP. At 48 h after transfection, cells were processed for double-label
immunofluoresence microscopy with use of anti-human GFAP monoclonal antibody (SMI-21) and anti-panGFAP polyclonal antibodies
(3270). When expressed in mouse primary astrocytes, wild-type GFAP formed filaments (arrows in A) that colocalized with the endogenous
mouse GFAP (arrows in B). The expression of human R416W GFAP resulted in both filamentous (arrowheads in C) and aggregate staining
patterns (arrows in C), which also costained with the endogenous mouse GFAP (arrows and arrowheads, respectively, in D). Bars p 10
mm. (A color version of this figure is available in the online edition of the journal.)
organization of the GFAP filaments preceding the eventual
collapse of the network.
Detection of R416W GFAP in Alexander Disease Brain
with Mutant-Specific Monoclonal Antibodies
The amino acid sequences of mouse and human GFAP are
highly homologous, with 91% identity and 95% similar-
ity,39 but species differences could influence the assembly
properties of the mutant human R416W GFAP in mouse
astrocytes. To follow the fate of the human R416W GFAP
in the presence of the endogenous wild-type human GFAP,
we sought to develop mouse monoclonal antibodies that
specifically recognized human R416W GFAP but not wild-
type GFAP, and vice versa (see the “Material and Methods”
section for details). The immunogen specific for the wild
type failed to elicit any GFAP monoclonal antibodies. The
R416W GFAP peptide, however, yielded two monoclonal
antibodies, 19.2 and 1A3, that recognized R416W GFAP
but not wild-type GFAP, as judged by immunoblots of pu-
rified, recombinant proteins (fig. 8A). In addition, neither
of these monoclonal antibodies crossreacted with a lysate
from a normal brain or with a lysate from a brain con-
taining another GFAP mutation commonly associated with
Alexander disease, R239C, and both produced signals from
lysates of R416W brain that were nearly identical to those
of the control SMI-21 monoclonal antibody (fig. 8A). Suit-
ability for immunohistochemistry was demonstrated by
immunostaining SW13/cl2 cells transfected with vectors
expressing either the mutant R416W or wild-type protein
(data not shown).
The R416W GFAP–specific monoclonal antibodies then
allowed us to determine whether R416W GFAP incorpo-
rated into Rosenthal fibers, normal-appearing filaments,
or both. Staining of normal, control brain was first tested
as a negative control. Control brain was readily stained
by a standard, GFAP polyclonal antibody (fig. 8B), but no
Figure 8. Characterization of R416W GFAP-specific antibodies and demonstration of its presence in Rosenthal fibers. A, Immunoblots,
performed as described in the “Material and Methods” section, with use of purified, recombinant human wild-type (hGF-WT) and R416W
(hGF-R416W) GFAP and lysates from brain samples taken from either control human (WT) or patients with Alexander disease that harbor
either an R239C mutation (R239C) or an R416W mutation (R416W) in GFAP. The general anti-human GFAP monoclonal antibody (SMI-
21) reacts with all samples, whereas the anti-R416W monoclonal antibodies (1A3 and 19.2) produce signals from R416W-containing
samples only, with the pattern for the R416W patient lysate identical to that of SMI-21. The identity of the immunopositive bands
above and below the prominent GFAP-positive band are as yet unknown. The lower bands most likely correspond to degradation products,
since these are normally seen in control brain samples. The upper bands are common to both the R239C and R416W samples, suggesting
these are a common feature of Alexander disease pathology, but, as yet, the reason for their slower electrophoretic mobility is unknown.
Panels B and C are striatum in a control (normal) brain stained with standard polyclonal GFAP antibody (B) and by R416W monoclonal
antibody 19.2 (C). Note that the R416W antibody does not crossreact with normal human brain tissue. Panels D–F are brain sections
from a patient with the R416W GFAP mutation that are stained with the monoclonal 19.2 antibody and then are visualized by either
peroxidase- (D) or rhodamine-tagged secondary antibodies (F) or are stained with the rabbit polyclonal GFAP antibody (Dako) and then
are detected with FITC-tagged secondary antibodies (E). Nuclei are counterstained with Hoechst 33258 (E and F [see the “Material and
Methods” section for procedure details]) to assist comparison of the panels E and F. Numerous Rosenthal fibers are stained around their
periphery (arrows in E and F), a feature often reported for these aggregates (e.g., the work of Tomokane et al.6). Normal-looking GFAP
filaments are also stained by the R416W-specific mAb (arrowheads in F) and can be detected by the diffuse staining in other parts of
the section.
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signal was produced with the R416W antibody (fig. 8C),
confirming the immunoblot results that the R416W anti-
body does not crossreact with normal human brain GFAP.
On the other hand, the R416W antibody strongly stained
brain from a patient with Alexander disease who harbored
an R416W mutation, with use of either peroxidase (fig.
8D) or fluorescent (fig. 8F) detection methods. This stain-
ing was apparent both along the periphery of the Rosen-
thal fibers and in normal-appearing filaments (fig. 8F) and
largely colocalized with staining of total GFAP (fig. 8E).
These data confirm the specificity of the R416W antibod-
ies produced. Importantly, they also demonstrate, for the
first time, that the mutant protein is stably expressed in
patients with the R416W mutation and that it is incor-
porated into both filaments and Rosenthal fibers.
Assembly Properties of Mutant GFAP Expressed in Human
Cells Containing Endogenous GFAP Filament Networks
These R416W GFAP–specific monoclonal antibodies also
permitted us to follow the fate of R416W GFAP when tran-
siently expressed in human astrocytoma U343MG cells.
This cell system would be expected to better mimic the
scenario of R416W GFAP being expressed in a human
astrocyte cell background and removes potential species
conflicts. In this model system, R416W GFAP induced the
formation of GFAP-rich aggregates (fig. 9A and 9B; arrows).
These data show that R416W GFAP is capable of disrupting
the endogenous networks of wild-type GFAP filaments
within the context of a human astrocytoma cell line and
once again demonstrate the dominant negative potential
of the mutant R416W GFAP on the endogenous IFs.
Similarities between the R416W-Induced Aggregates
in Transfected Cells and Rosenthal Fibers
In previous studies of Alexander disease pathology, several
other proteins were found to associate with Rosenthal fi-
bers, including the small heat shock proteins (sHSPs) aB-
crystallin6 and HSP27.40 We investigated whether these
proteins would associate with the aggregates of R416W
GFAP formed in the U343MG astrocytoma cells (fig. 9C–
9F). Both aB-crystallin (fig. 9D; arrows) and HSP27 (fig.
9F; arrows) colocalized with the GFAP-containing aggre-
gates in these cells (fig. 9C and 9E, respectively; arrows).
Rosenthal fibers are also ubiquitinated.6 That the GFAP
aggregates in transfected cells are also ubiquitinated was
demonstrated by cotransfection of His6-myc tagged ubi-
quitin26 along with R416W GFAP into the human astro-
cytoma cells (fig. 9G and 9H; arrows). Thus, the aggregates
formed by R416W GFAP in the transiently transfected hu-
man astrocytoma cells have many features reported else-
where and expected for Rosenthal fibers.41
To obtain biochemical evidence of the similarities be-
tween the Rosenthal fibers in patients and the R416W
GFAP aggregates formed in the transfected U343MG cells,
we extracted the cells and monitored the solubility of the
GFAP and the associated protein chaperones (fig. 9I). With
use of an extraction buffer containing deoxycholate, wild-
type GFAP was almost completely extracted from both the
untransfected (fig. 9I; Mock) and wild-type GFAP trans-
fected cells (fig. 9I; WT), conditions that also extracted aB-
crystallin, HSP27, and HSP70 (fig. 9I; Mock and WT). In
contrast, R416W GFAP remained entirely in the pellet frac-
tion of the extracted cells that had been transiently trans-
fected with R416W GFAP (fig. 9I; R416W). Interestingly,
when the immunoblots of the supernatant and pellet frac-
tions were also probed with antibodies toaB-crystallin (fig.
9I; aB-cry), HSP27 (fig. 9I; HSP27), and HSP70 (fig. 9I;
HSP70), a significant proportion of both aB-crystallin and
HSP27—but not HSP70—remained in the pellet fractions
of R416W GFAP–transfected cells (fig. 9I; R416W). These
data show that a proportion of both sHSPs is associated
with the insoluble R416W GFAP. Since HSP7027 was com-
pletely extracted from the R416W GFAP–transfected cells
under these conditions (fig. 9I; HSP70), the association of
the sHSPs with R416W GFAP is specific and not a general
property for all protein chaperones.
Discussion
The R416W Mutation in GFAP: A Dominant Mutation That
Affects Interfilament Interactions
In this study, we investigated the properties of the com-
mon Alexander disease–causing R416W GFAP mutation
to obtain insights into the initial stages of the disease pro-
cess. We demonstrated that this R416W GFAP mutation
dramatically alters assembly, both in vitro and in trans-
fected cells (figs. 1, 2, 4, 7, and 9), and does so in a dom-
inant manner. The mutant protein can also disturb en-
dogenous IF networks in cultured cells, including those of
vimentin (fig. 3D), keratin (fig. 4), and GFAP (figs. 7 and
9A). The effects of R416W GFAP are different in several
respects from those of R239C, the only other Alexander
disease–causing mutation that has been studied in detail.21
When assembled in vitro, the R239C mutant formed IFs
that appeared indistinguishable from wild-type filaments,21
whereas the R416W GFAP formed short filament inter-
mediates that associated laterally (fig. 1). Despite this dif-
ference, we show here that both the R239C and the R416W
GFAP form aggregates when expressed in either the vi-
mentin-negative SW13/cl.2 cell line or the primary mouse
astrocytes lacking both vimentin and GFAP (fig. 2), con-
firming some of the results in a previous study.21 When
R239C GFAP was transiently expressed in primary rat as-
trocytes, however, its assembly properties were not radi-
cally different from those of transiently expressed wild-
type GFAP.21 In contrast, we found that the R416W mu-
tant invariably formed aggregates when transiently over-
expressed in several different cell lines, including primary
mouse astrocytes (figs. 2 and 7) and human astrocytoma
cells (fig. 9B). Despite these differences, both mutations
were found to increase the resistance of GFAP to extraction
(figs. 5 and 9I).21 Taken together, these data indicate that,
whereas the immediate structural consequences of differ-
Figure 9. The similarity between Rosenthal fibers and GFAP aggregates formed in transfected human astrocytoma cells. U343MG cells
were transiently transfected with R416W GFAP and were routinely stained with rabbit polyclonal antibodies (3270) to GFAP (A, C, E,
and G) and then were double stained with mouse monoclonal antibodies specific to R416W GFAP (B), aB-crystallin (aB-cry) (D), or
HSP27 (F). Notice that the GFAP containing aggregates are also positive for both aB-crystallin and HSP27 (arrows in C–F). To demonstrate
the presence of ubiquitin in the GFAP aggregates, cells were cotransfected with His6-myc ubiquitin as well as R416W GFAP and then
were stained with rabbit polyclonal antibodies to GFAP (G) and the mouse monoclonal antibodies that recognize the myc epitope (H),
showing that the GFAP aggregates contain ubiquitin. Barsp 10 mm. I, Wild-type and R416W GFAP (R416W) were transiently expressed
in the human astrocyte cell line U343MG, and supernatant (S) and pellet (P) fractions were prepared from these culture and were
compared with mock transfected cells. Cell fractionation used HEB, which almost completely solubilized wild-type GFAP. R416W GFAP,
on the other hand, remained in the pellet fraction. Immunoblots of the cell fractions were probed with antibodies to GFAP, aB-crystallin,
HSP27, HSP70, and finally actin, which was used as a loading control. Notice that, when cells were transfected with R416W GFAP, a
significant proportion of the HSP27 and aB-crystallin but not HSP70 remained in the pellet fraction along with the R416W GFAP. Both
the sHSPs and R416W GFAP were more resistant to extraction compared with these proteins in the wild-type GFAP transfected cells. (A
color version of this figure is available in the online edition of the journal.)
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Figure 10. GFAP aggregation caused by the R416W mutation
induces sHSP association and the association of ubiquitin as early
events in the etiology of Alexander disease. The presence of the
R416W GFAP mutation decreases the solubility of the GFAP fila-
ments, probably by altering the filament-filament interactions in
a manner that encourages aggregation. This is accompanied by
the sequestration of the sHSP protein chaperones—aB-crystallin
and HSP27 (shaded circles)—and GFAP into aggregates. Both pro-
teins also localize to Rosenthal fibers, which also contain ubiquitin
(Ub). The filament aggregates undergo a maturing process, with
the additional posttranslational modification of integral compo-
nents, such as the phosphorylation64 and ubiquitination8 of aB-
crystallin to form the Rosenthal fibers. The model is not exclusive
to R416W GFAP, since Rosenthal fibers are a characteristic diag-
nostic feature of Alexander disease.12 Other GFAP mutations differ
in the details of the mechanism by which they produce aberrant
filament-filament interactions leading to the formation of stabi-
lized aggregates, but, once formed, they then follow a common
pathway to Rosenthal fiber formation. Increased GFAP filament
stability and the specific association of sHSPs are predicted to be
the earliest events in the development of Alexander disease. (A
color version of this figure is available in the online edition of
the journal.)
ent GFAP mutations are likely to differ, as has been found
for other intermediate filament proteins,10,42,43 there will
likely be common consequences that lead to Alexander
disease.
The RDG-Containing Motif and Its Role in Filament
Assembly
The R416W mutation lies within the RDG motif that is
conserved within the tail domain of nearly all of the type
III IF proteins. Previous studies of GFAP had concluded
that the RDG motif was important to filament assembly,
but only in the context of the rest of the C-terminal do-
main.44 Our assembly data, presented here, show that
changing the precise sequence of this motif to WDG does
have dramatic effects on GFAP assembly (figs. 1 and 2).
Change of the equivalent arginine (R449) to proline in
vimentin also severely disrupted the in vitro assembly and
network formation in transiently transfected cells.45 These
combined data suggest that this arginine residue in the
RDG motif within the C-terminal domain is very impor-
tant for the assembly IF proteins with the motif.
Previous studies proposed that the C-terminal domain
associates intramolecularly with the C-terminal end of the
rod domain.46 Crystallization of the helix IIB rod domain
suggests that the two a helices fold away from the dimer
axis,17 which is consistent with the hypothesis that the
C-terminal domain could form a surface-exposed loop
structure and prevent inappropriate subunit interactions
in the self-assembly process.46 This offers an explanation
of the altered width of vimentin filaments assembled from
tail-truncated and deleted forms of vimentin47 and the
changed in vitro assembly characteristics of the R416W
GFAP we report here (fig. 1).
Our studies also suggest that the RDG motif will con-
tribute to interfilament interactions as well as subunit or-
ganization within the IF. We have demonstrated the in-
creased tendency of R416W GFAP to aggregate in vitro
(fig. 1) as well as in transfected cells (figs. 2, 4, 7, and 9).
Studies of keratins also show that the C-terminal domain
is very important in promoting filament-filament inter-
actions.48–50 Together with our data presented here, a con-
sensus is thus beginning to emerge that C-terminal se-
quences of cytoplasmic IFs help regulate both intra- and
interfilament associations.
The Mutant R416W GFAP: A Component of Rosenthal
Fibers
The presence of Rosenthal fibers has been documented in
two cases of Alexander disease caused by the R416W GFAP
mutation.6,9,51 For one of these cases, we show, for the first
time for any Alexander disease case, that the mutant GFAP
is present as the defining histopathological feature (fig. 8D
and 8F). This is also the first time for any IF-based human
disease that the link between the presence of the mutated
protein and a characteristic histopathogical IF aggregate
has been rigorously shown. In a case of epidermolysis bul-
losa simplex, a keratin-blistering disease, the loss of an
epitope was used to confirm the genotype of patients,52
but this reagent was unable to demonstrate the presence
of the mutant keratin 5 in the aggregates found in kera-
tinocytes. Another study described the generation of a poly-
clonal antibody specific for a keratin 8 variant (R340H),
which may predispose carriers to liver disease,53 but these
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antibodies were used only for immunblotting studies.
Even in the case of Mallory bodies formed as a result of
alcoholic hepatitis, where antibodies were developed that
selectively stained the Mallory bodies and not the sur-
rounding keratin filaments, the antibodies still detected
wild-type keratins.54 Our antibody reagents are therefore
the first to specifically identify a mutant missense IF pro-
tein in the presence of its wild-type counterpart. These
antibodies allowed us to demonstrate that the mutant pro-
tein is a component of Rosenthal fibers in human patient
brain tissue (fig. 8D and 8F) and also in GFAP-containing
aggregates of transfected human astrocytoma cells (fig.
9B).
Association of aB-Crystallin and HSP27 with R416W GFAP
Aggregates
We also discovered that the protein chaperones aB-crys-
tallin and HSP27 specifically associate with the GFAP ag-
gregates that are formed in transfected cells that express
R416W GFAP. Both chaperones are components of Ro-
senthal fibers found in patients, including those with the
R416W mutation.6,40 These chaperones normally minimize
filament-filament associations,27 and their overexpression
can dissolve accumulations of wild-type GFAP filaments.55
Their presence, however, in both brain astrocytes of pa-
tients with Alexander disease and in cultured cells does
not prevent the changes in GFAP-filament solubility, fil-
ament aggregation, or the formation of Rosenthal fibers
by R416W GFAP. The association of HSP27 and aB-crys-
tallin with R416W GFAP and resistance to extraction is
likely due to the altered filament properties induced by
this mutation. Although other stresses have been shown
to stimulate the association of both HSP27 and aB-crys-
tallin with GFAP filaments,27,40 those studies involved wild-
type proteins. Our data show that it is specifically the
presence of the R416W GFAP, and not wild-type GFAP,
that both stabilizes GFAP and leads to the sequestration
of sHSPs (figs. 9C–9F and 9I).
The sequestration of HSP27 and aB-crystallin could po-
tentially compromise the astrocyte stress response and
therefore contribute to the initiation of Alexander disease.
For example, it has already been shown that either the
reduction of HSP27 or the loss of aB-crystallin compro-
mises cytoskeletal integrity and function56 or induces mus-
cular atrophy,57 respectively. HSP27 is a key protein in
protecting cells, including neurons,58 against apoptosis by
inhibiting caspase activity59 and preserving mitochondrial
function.60 HSP27 has also been implicated in regulating
the stress response through the ubiquitin-mediated pro-
teosomal regulation of the key transcription factor, NFkB.61
Importantly, HSP27 protects cells against other protein
aggregation–based diseases caused by huntingtin62 and a-
synuclein.63 Such studies identify diminution of sHSP lev-
els as a potential Achilles’ heel in the cellular response to
protein aggregate–based diseases that require either up-
regulation58 or overexpression63 to ameliorate the disease
phenotype. These observations suggest that the early se-
questration of sHSPs into GFAP aggregates (this study) and
Rosenthal fibers6 is a key event at the onset of Alexander
disease. Figure 10 incorporates these ideas into a diagram
of the events that we believe to be important in the early
stages of Alexander disease.
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